New Brunswick, NJ, December 18, 2014 ― HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer Dean J. Paranicas has authored the following op-ed on the life sciences and the value of medical innovation.
* * *
Medical innovations produced by American life sciences companies have vastly improved the human condition. Our pharmaceutical, biotech, medical technology, device and diagnostics companies have helped people live longer, with less pain and greater quality of life.
Over the past century, the life sciences has eradicated some of the world’s most dreaded diseases such as polio and smallpox. More recently, the industry has made other diseases such as breast cancer, HIV/AIDS, heart disease and lung cancer no longer the death sentences that they once were.
Collectively, new therapies are the greatest contributors to increased life expectancy. According to the National Bureau of Economic Research (NBER), between 1960 and 1997, new therapies accounted for 45 percent of the increase in life expectancy in 30 developing and high-income countries. Between 2000 and 2009, new therapies accounted for 73 percent of the increased life expectancy for these countries.
Despite the dramatic life-saving advancements that the life sciences sector has made, our work is far from done. Read the rest of this entry »
This Funding Opportunity Announcement (FOA) invites applications to establish an NIA Coordination Center to facilitate and support the Replication Phase of the Alzheimer’s Disease (AD) Sequencing Project (ADSP) activities. The Coordinating Center for the Genetics and Genomics of Alzheimer’s Disease (CGAD) will serve as the focal point for ADSP replication phase joint data analysis, harmonization, and sharing. The FOA is intended to support a major component of the full range of analysis for the Replication Phase of the ADSP.
For more information, click here.